1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Bioinfra Life Science, Inc.

Bioinfra Life Science, Inc.

KKRX:266470
95.00
KRW
-3.00
(-3.06%)
-266.58EPS
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
121.54
105.94
112.89
138.94
75.34
101.4
105.6
92.32
11.55
45.59
131.95
Basic EPS, GAAP
-361
-309
-277
-243
-326.84
-174
-103
-174
-190
-93.19
-266.58
Free Cash Flow per Basic Share
-318.46
-295.96
-299.18
-193.89
-271.03
-250.35
-159.15
-108.28
-80.51
-55.38
-219.17
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
637.39
326.84
197.67
-20.4
-112.56
137.57
36.29
-135.2
109.15
19.35
-98.57
Tangible Book Value per Share
572.22
280
155.29
-59.13
-152.22
103.64
5
-161.59
97.12
19.35
-135.73
Basic Weighted Avg Shares
13
13
14
13
14
14
14
14
16
28
13
Sales/Revenue/Turnover
1,550
1,370
1,551
1,875
1,043
1,426
1,492
1,302
189
1,270
1,779
Operating Margin (%)
-227.51
-227.65
-232.45
-179.72
-392.4
-302.95
-117.65
-166.59
-1,077.07
-109.29
-199.78
Depreciation Expense
128
178
273
347
400
383
357
291
183
121
376
Net Income, GAAP
-4,603
-3,996
-3,807
-3,278
-4,524
-2,448
-1,455
-2,453
-3,108
-2,597
-3,594
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-297.02
-291.67
-245.38
-174.89
-433.79
-171.59
-97.54
-188.48
-1,644.68
-204.4
-202.04
Working Capital
6,033
3,560
2,019
4,637
1,125
2,166
827
-1,315
27
-1,244
3,580
LT Debt
576
- -
447
15
61
- -
66
- -
- -
- -
11
Total Equity
8,981
4,605
2,953
-114
-1,425
2,532
1,103
-1,316
3,041
539
-1,206
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-58.82
-103.02
- -
- -
- -
-118.68
- -
- -
-145.05
- -

Capital Structure

KRW

•

in mil. unless spec.
Sep'19
Dec'19
Mar'20
ST Debt
55
4,181
4,388
LT Borrowings
485
- -
- -
LT Finance Leases
21
15
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
- -
- -
- -

Working Capital

KRW

•

in mil. unless spec.
Sep'19
Dec'19
Mar'20
Total Current Assets
7,351
9,951
8,942
Cash, Cash Equivalents & STI
5,536
8,541
7,485
Accounts Receivable, Net
1,731
1,364
1,351
Inventories
- -
- -
- -
Total Current Liabilities
561
5,314
5,362
Payables & Accruals
- -
- -
- -
ST Debt
55
4,181
4,388
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-193.36%
-82.27%
Free Cash Flow
- -
-14.19%
17.15%
Net Income, GAAP
- -
-1.52%
-16.46%
Sales/Revenue/Turnover
- -
103.06%
572.2%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,302
2024
- -
- -
- -
- -
189
2025
- -
- -
- -
- -
1,270

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-174
2024
- -
- -
- -
- -
-190
2025
- -
- -
- -
- -
-93.19

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Duk-Yoon Lee
Full Time Employees
3
Sector
Health technology
Industry
Medical specialties
Address
Seoul South Korea
IPO Date
Jul 22, 2020
Website
bioinfra.co.kr
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Bioinfra Life Science, Inc. is a South Korea-based biotechnology and healthcare company specializing in multi-biomarker in-vitro diagnostics, targeted drug delivery platforms, and medical aesthetic technologies. Founded in 2001 and headquartered in Incheon, South Korea, the company operates primarily across diagnostic testing services, therapeutic development, and medical devices. Bioinfra Life Science, Inc. provides a comprehensive portfolio of products and clinical services, including the i-Finder smart cancer screening platform, a multi-biomarker blood analysis service that measures 19 protein biomarkers via proprietary artificial intelligence algorithms to assess early-stage risk profiles for eight major malignancies, including lung, stomach, liver, colorectal, pancreatic, breast, ovarian, and prostate cancers, as well as chronic metabolic disorders; specialized diagnostic assay panels such as i-Finder LC, X-FINDER, and M-FINDER for precision oncology; ultrasound-responsive microbubble targeted drug delivery systems (DDS) engineered for selective oncology therapeutics and gene-directed treatments; and commercial aesthetic and transdermal drug delivery systems, including the SONO CUBE ultrasound beauty device and the SONOSKIN cosmeceutical product line powered by its proprietary T&F ultrasound technology. The company primarily markets its solutions to general hospitals, health checkup centers, clinical diagnostic laboratories, and medical aesthetic clinics across South Korea and international markets throughout the Asia-Pacific region. In recent company developments, Bioinfra Life Science restructured its executive management team with the appointment of Seung-jun Kim as Chief Executive Officer; advanced the commercial and clinical expansion of its ultrasound drug delivery platform into dermatology and alopecia treatment indications; entered into strategic cross-border partnerships and service supply agreements with healthcare institutions, including Raffles Hospital and Oracle Medical Group; and completed capital adjustments and financing measures to advance its clinical pipeline for targeted cancer therapies and expand the market reach of its diagnostic screening services.